Loading
A phase 2 trial of Durvalumab, Ceralasertib, Olaparib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy is a phase 2 interventional study registered as NCT03334617 by AstraZeneca, with 528 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-09-13. Interventions recorded: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
528 enrolled.
80% CI 2.6 to 23.4; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication · 80% CI 0.5 to 17.3 · 80% CI 0.0 to 9.9 · 80% CI 0.5 to 15.9 · 80% CI 0.0 to 9.5 · 80% CI 0.0 to 9.9 · 80% CI 15.7 to 38.5 · 80% CI 3.0 to 17.2 · 80% CI 4.3 to 15.4 · No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… · 80% CI 0.5 to 15.9 · 80% CI 0.0 to 22.6 · 80% CI 0.4 to 14.7 · 80% CI 11.0 to 36.6 · 80% CI 20.7 to 51.8 · 80% CI 11.5 to 38.1 · 80% CI 0.0 to 14.2 · 80% CI 6.3 to 33.4 · 80% CI 2.2 to 20.7 · 80% CI 0.0 to 6.5 · 80% CI 3.2 to 28.4 · 80% CI 0.3 to 9.9
Source80% CI 5.26 to 15.97; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication · 80% CI 5.29 to 10.84 · 80% CI 4.93 to 10.28 · 80% CI 9.33 to 20.86 · 80% CI 3.55 to 6.51 · 80% CI 9.72 to 12.55 · 80% CI 14.16 to 22.80 · 80% CI 5.82 to 11.30 · 80% CI 9.13 to 15.80 · No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… · 80% CI 7.59 to 15.74 · 80% CI 4.90 to 11.99 · 80% CI 7.39 to 20.96 · 80% CI 6.57 to 12.42 · 80% CI 8.90 to 20.60 · 80% CI 11.86 to 19.88 · 80% CI 6.08 to 17.18 · 80% CI 5.59 to 8.64 · 80% CI 7.39 to 20.50 · 80% CI 4.01 to 10.05 · 80% CI 4.37 to 12.71 · 80% CI 5.85 to 9.13
Source80% CI 1.41 to 5.26; Figures from the ClinicalTrials.gov results section (first posted 2025-10-27), not from a publication · 80% CI 1.38 to 1.81 · 80% CI 2.10 to 4.93 · 80% CI 2.69 to 4.37 · 80% CI 1.64 to 2.99 · 80% CI 2.83 to 6.14 · 80% CI 5.59 to 9.43 · 80% CI 1.91 to 3.09 · 80% CI 3.02 to 4.96 · No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… · 80% CI 1.41 to 2.76 · 80% CI 1.35 to 1.81 · 80% CI 1.74 to 4.17 · 80% CI 2.33 to 5.45 · 80% CI 5.32 to 5.72 · 80% CI 2.56 to 9.36 · 80% CI 2.14 to 7.62 · 80% CI 1.41 to 2.23 · 80% CI 2.83 to 7.33 · 80% CI 1.61 to 2.56 · 80% CI 1.71 to 2.79 · 80% CI 2.73 to 3.02
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)primary | Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 9.5% | - | - | link |
| Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 4.8% | ||||
| Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg | 22 | 0% | ||||
| Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg | 23 | 4.3% | ||||
| Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg | 23 | 0% | ||||
| Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg | 22 | 0% | ||||
| Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg | 31 | 25.8% | ||||
| Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg | 37 | 8.1% | ||||
| Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg | 58 | 8.6% | ||||
| Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg | 1 | No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… | ||||
| Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg | 23 | 4.3% | ||||
| Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg | 9 | 0% | ||||
| Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg | 25 | 4% | ||||
| Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 23 | 21.7% | ||||
| Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 20 | 35% | ||||
| Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg | 22 | 22.7% | ||||
| Module 8 Cohort A.8.ATM: Ceralasertib 240 mg | 15 | 0% | ||||
| Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg | 18 | 16.7% | ||||
| Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg | 24 | 8.3% | ||||
| Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg | 34 | 0% | ||||
| Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg | 17 | 11.8% | ||||
| Module 11 Cohort C.11.240: AZD6738 240 mg | 38 | 2.6% | ||||
| Overall Survival (OS) | Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 9.63 months | - | - | link |
| Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 5.75 months | ||||
| Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg | 22 | 7.16 months | ||||
| Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg | 23 | 15.51 months | ||||
| Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg | 23 | 6.01 months | ||||
| Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg | 22 | 11.2 months | ||||
| Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg | 31 | 15.8 months | ||||
| Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg | 38 | 10.22 months | ||||
| Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg | 58 | 11.37 months | ||||
| Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg | 1 | No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… | ||||
| Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg | 23 | 10.97 months | ||||
| Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg | 9 | 7.06 months | ||||
| Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg | 25 | 12.78 months | ||||
| Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 23 | 9.53 months | ||||
| Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 20 | 10.61 months | ||||
| Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg | 22 | 14.19 months | ||||
| Module 8 Cohort A.8.ATM: Ceralasertib 240 mg | 15 | 14.23 months | ||||
| Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg | 19 | 7.95 months | ||||
| Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg | 24 | 12.91 months | ||||
| Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg | 34 | 5.95 months | ||||
| Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg | 17 | 7.03 months | ||||
| Module 11 Cohort C.11.240: AZD6738 240 mg | 38 | 6.6 months | ||||
| Progression-Free Survival (PFS) Per RECIST v1.1 | Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 2.79 months | - | - | link |
| Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg | 21 | 1.41 months | ||||
| Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg | 22 | 3.38 months | ||||
| Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg | 23 | 4.17 months | ||||
| Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg | 23 | 1.68 months | ||||
| Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg | 22 | 3.09 months | ||||
| Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg | 31 | 7.43 months | ||||
| Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg | 38 | 2.96 months | ||||
| Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg | 58 | 4.21 months | ||||
| Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg | 1 | No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the mod… | ||||
| Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg | 23 | 1.61 months | ||||
| Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg | 9 | 1.41 months | ||||
| Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg | 25 | 2.69 months | ||||
| Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 23 | 2.83 months | ||||
| Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg | 20 | 5.52 months | ||||
| Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg | 22 | 4.17 months | ||||
| Module 8 Cohort A.8.ATM: Ceralasertib 240 mg | 15 | 3.42 months | ||||
| Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg | 19 | 1.48 months | ||||
| Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg | 24 | 3.68 months | ||||
| Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg | 34 | 1.68 months | ||||
| Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg | 17 | 2 months | ||||
| Module 11 Cohort C.11.240: AZD6738 240 mg | 38 | 2.86 months |
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Ceralasertib, Durvalumab, AstraZeneca, Non-small-cell lung cancer.
Shares Ceralasertib, AstraZeneca, Non-small-cell lung cancer.
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Ceralasertib, Durvalumab, AstraZeneca.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Oleclumab, AstraZeneca, Non-small-cell lung cancer.
Shares Olaparib, Durvalumab, AstraZeneca, Small-cell lung cancer.